Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices. Presenting below are its Q1 FY26 earnings results.
Q1 FY26 Earnings Results
-
Total Income: ₹403 crores, up 4.68% YoY (Q1 FY25: ₹385 crores) and up 13.2% QoQ (Q4 FY25: ₹393.05 crores).
-
Total Expenses: ₹323.28 crores, up 6.28% YoY.
-
Profit Before Tax (PBT): ₹121.62 crores, up 23.5% YoY (Q1 FY25: ₹98.46 crores) and up 31.5% QoQ.
-
Profit After Tax (PAT): ₹93.08 crores, up 25.68% YoY (Q1 FY25: ₹74.04 crores), up 36.2% QoQ.
-
Earnings Per Share (EPS): ₹9.19, up 19.2% YoY (Q1 FY25: ₹7.70).
-
Operating EBITDA Margin: 26.3% in Q1 FY26.
-
PAT Margin: 20.9%, expanded by ~250bps YoY.
-
Domestic Revenue: Grew 20.1% YoY, reflecting strong traction.
-
International Revenue: Contributes ~70% of total, declined 0.9% YoY due to short-term demand and tariff issues.
Management Commentary & Strategic Decisions
-
Management emphasized continued strong domestic momentum, healthy margins, and enhanced PAT even as global geopolitical/trade headwinds impacted exports in the quarter.
-
The company maintains zero net debt with liquidity of ₹1,248.6 crore, and CapEx of ₹95 crore in Q1 to build infrastructure for future growth.
-
Critical Care, Cardiology, and Renal Divisions continue robust expansion, positioning Poly Medicure strongly for future opportunities across therapies and geographies.
-
Management expects 5–10% international business growth in coming quarters, supported by ongoing product innovation and sustainability focus.
-
Production capacity exceeds 1.8 billion devices annually, with a diverse portfolio over 12 therapy areas and 125+ export markets.
Q4 FY25 Earnings Results
-
Total Income: ₹441 crores.
-
Total Expenses: ₹321 crores.
-
PBT: ₹92.46 crores.
-
PAT: ₹92 crores.
-
EPS: ₹9.06
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.